Clinical trials: Type 1 Diabetic Nephropathy
Cardiovascular Disease, Diabetic Nephropathy
Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy
The primary objective is to assess the impact of three months of treatment with an active vitamin D analogue on a risk marker for excess overall mortality and cardiovascular morbidity/mortality in Type 1 diabetic patients with…
- Trial name
- NCT01331317
- Testing
- Paricalcitol
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Peter Rossing
Type 1 Diabetes Mellitus
The MICRON Study - A Steno 1 Substudy
The goal of this observational study is to compare cardiac and renal oxygen consumption among subjects with type 1 diabetes treated with either multifactorial intervention or according to the current standard care.
- Trial name
- MICRON (NCT07270172)
- Where
- 5 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 2 Diabetes
The Hong Kong Diabetes Biobank
Asia is in the midst of an epidemic of diabetes. Epidemiological figures suggest that there are more than 110 million people affected by diabetes in China, with a significant proportion of young adults already affected.
- Conditions
- Diabetes Mellitus, Type 2 Diabetes, Type 1 Diabetes, Diabetic Nephropathies
- Trial name
- HKDB (NCT05282680)
- Testing
- prospective observational study
- Where
- Hong Kong
- Volunteers
- 48,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Based upon the preclinical evidence in models of diabetic nephropathy under conditions approximating both type I and II diabetes, treatment with alagebrium appears to have favorable and advantageous effects on the biochemical…
- Trial name
- NCT00557518
- Testing
- Alagebrium
- Where
- 6 sites in Australia, Denmark
- Volunteers
- 80 people
- Sponsor
- Synvista Therapeutics, Inc
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease.
- Trial name
- peeDIAB2 (NCT02164279)
- Testing
- Urinary sample collection
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Nephropathy, Diabetic Nephropathies
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes.
- Conditions
- Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1, Albuminuria
- Trial name
- PLUTO (NCT06147232)
- Testing
- Sotagliflozin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 1 Diabetes
Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study
Current medical therapies are not able to prevent progression of established macroproteinuira (i.e. diabetic nephropathy) to end-stage renal failure in type 1 (insulin dependent) diabetic patients.
- Trial name
- PANCREAS (NCT01067950)
- Testing
- Isolated Pancreas Transplant, Intensive Insulin Therapy
- Where
- 7 sites in United States, Brazil and 3 more
- Volunteers
- 180 people
- Sponsor
- Nantes University Hospital
Type1diabetes
Advanced Glycation Products and Vascular Complications in Type 1 Diabetes
DIABAGE (Diabetes Advanced Glycation End products) study was conducted between 2015 and 2017. It included 196 type 1 diabetic patients with more than 10 years of diabetes.
- Trial name
- DIABAGE (NCT06458088)
- Where
- France
- Volunteers
- 196 people
- Sponsor
- CHU de Reims
Diabetic Nephropathy
Adiponectin and Insulin Resistance in Diabetic Nephropathy
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB)…
- Trial name
- NCT00774904
- Testing
- Losartan
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xi'an Jiaotong University
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
The goal of this clinical trial is to develop and evaluate a novel diabetes ketoacidosis risk mitigation strategy to support the safe use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy in participants with type 1…
- Conditions
- Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis
- Trial name
- SCOUT-CKD (NCT07325201)
- Testing
- Sotagliflozin initiation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- HealthPartners Institute
Diabetic Nephropathies, Hypertension
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target of 130/80 mmHg after one year…
- Trial name
- NCT00153023
- Testing
- Telmisartan, Valsartan
- Where
- 111 sites in Czechia, Denmark and 11 more
- Volunteers
- 885 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathies, Coronary Artery Disease
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Despite improvements during the past 20 years in blood glucose and blood pressure control, diabetic kidney disease remains one of the most important causes of health problems in patients with diabetes.
- Trial name
- NCT02017171
- Testing
- Allopurinol
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 530 people
- Sponsor
- Alessandro Doria
Diabetic Nephropathy.
SLC2A1 Variants and Diabetic Nephropathy
Cells damaged by hyperglycemia are unable to downregulate glucose entrance in presence of high extracellular glucose resulting in intracellular activation of deleterious biochemical pathways.
- Trial name
- NCT01768611
- Where
- Brazil
- Volunteers
- 449 people
- Sponsor
- University of Sao Paulo General Hospital
Diabetic Nephropathies, Kidney Failure, Chronic
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes.
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Trial name
- SUGARNSALT (NCT06217302)
- Testing
- Sotagliflozin
- Where
- 19 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Alessandro Doria
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Matrix Metalloproteinases and Diabetic Nephropathy
Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs.
- Trial name
- NCT00067886
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Type 1 Diabetes Mellitus, Diabetic Retinopathy
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.
- Conditions
- Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
- Trial name
- FAME 1 EYE (NCT01320345)
- Testing
- Fenofibrate
- Where
- 24 sites in Australia, Hong Kong and 2 more
- Volunteers
- 412 people
- Sponsor
- University of Sydney
Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Stem Cell Therapy for Chronic Kidney Disease
The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus
- Trial name
- NCT04869761
- Testing
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- LaTonya J. Hickson
Type1diabetes, Type1 Diabetes Mellitus
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up…
- Conditions
- Type1diabetes, Type1 Diabetes Mellitus, Diabetic Kidney Disease, Juvenile Diabetes
- Trial name
- COFFEE (NCT03878277)
- Testing
- Starbucks® Cold brew - 325ml bottle
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver